6月5日 - ** 药物开发商 Phio Pharmaceuticals PHIO.O股价盘前上涨 12.4% 至 2.36 美元
** 券商H.C. Wainwright维持 "买入 "评级，并将目标价定为14美元。
** 新的预测价格比该股上次收盘价上涨了近七倍
** 我们认为 Phio 的发展还未被投资者察觉，我们看好该股的前景" - H.C. Wainwright
** 称该公司的主要资产皮肤癌疗法 PH-762 已经显示出 "令人印象深刻的临床活性，并在早期研究中表现出良好的安全性
** 券商认为，保持对合作机会的开放态度是 "在当前市场条件下一个未得到充分重视的立场"。
** 截至上一交易日收盘，股价累计上涨 16.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.